Hepatic Oncology (Jun 2020)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance

Devis Pascut,
Muhammad Yogi Pratama,
Claudio Tiribelli

Affiliations

Devis Pascut: 1Fondazione Italiana Fegato – ONLUS, Liver Research Center, AREA Science Park, ss14, Km163.5, Basovizza, 34149 Trieste, Italy
Muhammad Yogi Pratama: 1Fondazione Italiana Fegato – ONLUS, Liver Research Center, AREA Science Park, ss14, Km163.5, Basovizza, 34149 Trieste, Italy
Claudio Tiribelli: 1Fondazione Italiana Fegato – ONLUS, Liver Research Center, AREA Science Park, ss14, Km163.5, Basovizza, 34149 Trieste, Italy

DOI: https://doi.org/10.2217/hep-2020-0010
Journal volume & issue: Vol. 7, no. 2

Abstract

No abstracts available.

Published in Hepatic Oncology

ISSN: 2045-0923 (Print); 2045-0931 (Online)
Publisher: Taylor & Francis
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.tandfonline.com/journals/ihep20

About the journal